<DOC>
	<DOCNO>NCT01724944</DOCNO>
	<brief_summary>The purpose study determine role lymphadenectomy advenced ovarian cancer patient time interval debulking surgery neoadjuvant chemiotherapy . Moreover prospective trial , aim investigate prognostic role sistematic lymphadenectomy term percentage micrometastases detect , morbidity ( complication rate ) , progression free interval , overall survival , recurrence pattern .</brief_summary>
	<brief_title>LYmphadenectomy After NeoAdjuvant Chemotherapy</brief_title>
	<detailed_description>In patient advanced ovarian cancer ( FIGO stage III-IV ) , percentage 50 % 80 % lymph node metastasis diagnosis , mainly para-aorto-caval ( 48 % ) iliac area ( 49 % ) . In 1988 , FIGO include lymph node metastasis stage IIIC , although author argue node involvement constitute clinical course different IIIC cancer patient abdominal diffusion . Although demonstrated lymphadenectomy technically feasible relatively safe subset patient , however , burden certain percentage complication include limphocyst , lymphedema , hemorrhage , range 6 % 45 % . In addition , actual therapeutic role still controversial clear whether surgical procedure part stag tumor . Retrospective study show benefit overall survival patient ovarian cancer underwent lymphadenectomy associate optimal debulking ( residual tumor &lt; 1 cm ) . In recent publication SEER find number lymph node remove surgery advanced ovarian cancer independent prognostic factor . In literature one prospective randomize study lymphadenectomy advance ovarian cancer without node lesion macroscopically observe ( bulky node ) first surgery . The author report significant benefit term disease free survival ( DFS ) , term overall survival ( OS ) patient underwent systematic lymphadenectomy residual tumor &lt; 1 cm . Patients intra-abdominal residual tumor &lt; 1 cm could theoretically benefit systematic lymphadenectomy since lymph node metastases undetectable intraoperative assessment small 1 cm . About 20 % ovarian cancer patient stage III-IV , however , operable time diagnosis spread disease . In case , gold standard treatment consist submit patient Interval Debulking Surgery ( IDS ) neoadjuvant chemotherapy . The prognosis patient compare subjected primary surgery , residual tumor surgery , currently topic controversial debate . Recently , multicenter , randomize EORTC show difference prognosis primary surgery Interval Debulking Surgery population stratify residual tumor . There retrospective study consider presence lymph node metastases patient undergo Interval Debulking Surgery : percentage lymph node metastases subset varies 37.5 % 75 % . The purpose study ass whether systematic pelvic aortic lymphadenectomy part standard surgical procedure patient ovarian cancer underwent surgery neoadjuvant chemotherapy intra-abdominal residual tumor &lt; 1 cm . All patient candidate Interval Debulking Surgery present bulky node surgery intra-abdominal residual tumor &lt; 1 cm end surgery enrol study . The baseline assessment patient perform general blood test , CA 125 , CT thorax , abdomen , pelvis , anesthetic assessment , eligible , patient subject treatment . The enrollment period last 2 year achieve 65 patient study population . The median follow-up 6 month patient primary objective median 36 month secondary objective .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Age 18 75 year Patients affect advanced ovarian cancer ( FIGO stage IIIIV ) undergo &gt; 2 &lt; 7 cycle neoadjuvant chemotherapy base platinum taxanes . Clinical response ( instrumental serological ) complete partial . Residual intraabdominal tumor &lt; 1 cm . Absence disease macroscopically evident lymph node ( &gt; 1 cm ) Life expectancy least 4 week ECOG PS â‰¤ 2 Adequate respiratory function , hepatic , cardiac , bone marrow renal function ( creatinine clearance &gt; 60 mL / min accord Cockroft formula ) Patient psychologically able follow study procedures Patients severe impairment lung function , liver failure , allow access safety operate room . Not epithelial ovarian neoplasm borderline tumor Other invasive cancer last 5 year sign recurrence activity Patients intraabdominal residual tumor &gt; 1 cm Patients presence bulky node ( &gt; 1 cm ) intraoperative evaluation Diseases lymphatic system ( include lymphatic edema unknown origin )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Interval debulking surgery</keyword>
	<keyword>IDS</keyword>
	<keyword>NACT</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Lymphadenectomy</keyword>
	<keyword>Ovarian cancer</keyword>
</DOC>